• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $WST

    West Pharmaceutical Services Inc.

    Subscribe to $WST
    $WST
    Medical/Dental Instruments
    Health Care

    West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

    IPO Year:

    Exchange: NYSE

    Website: westpharma.com

    Peers

    $ATR

    Recent Analyst Ratings for West Pharmaceutical Services Inc.

    DatePrice TargetRatingAnalyst
    3/18/2025$275.00Outperform
    Evercore ISI
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    1/8/2025$400.00Buy
    Citigroup
    12/13/2024Peer Perform
    Wolfe Research
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    2/7/2024$323.00 → $536.00Hold → Buy
    Jefferies
    6/16/2023$390.00 → $405.00Neutral → Buy
    BofA Securities
    4/11/2023$330.00 → $400.00Equal-Weight → Overweight
    Stephens
    12/14/2022$250.00Hold
    Deutsche Bank
    11/30/2022$250.00Neutral
    UBS
    See more ratings

    West Pharmaceutical Services Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Michels Douglas A was granted 1,071 shares, increasing direct ownership by 2% to 45,171 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 5:04:01 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Pucci Paolo was granted 1,071 shares, increasing direct ownership by 11% to 10,947 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 5:00:01 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Haugen Janet Brutschea was granted 1,071 shares, increasing direct ownership by 433% to 1,318 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 4:54:17 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Friel Robert F was granted 1,071 shares, increasing direct ownership by 30% to 4,682 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 4:50:36 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Lai Goldman Myla was granted 1,071 shares, increasing direct ownership by 6% to 19,424 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 4:42:06 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Joseph Molly was granted 1,071 shares, increasing direct ownership by 59% to 2,884 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 4:38:59 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Hofmann Thomas W was granted 1,071 shares, increasing direct ownership by 2% to 44,637 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 4:35:19 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Keller Deborah L was granted 1,071 shares, increasing direct ownership by 11% to 10,657 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 4:32:47 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Feehery William F was granted 1,071 shares, increasing direct ownership by 4% to 31,363 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 4:30:52 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Lockhart Stephen H was granted 1,071 shares, increasing direct ownership by 65% to 2,708 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 4:28:54 PM ET
      $WST
      Medical/Dental Instruments
      Health Care

    West Pharmaceutical Services Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • West to Participate in Upcoming Investor Conferences

      EXTON, Pa., May 7, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the BofA Securities Annual Healthcare Conference on Wednesday, May 14, 2025 at 2:20 PM PT. It will also present at the William Blair 45th Annual Growth Stock Conference on Thursday, June 5, 2025 at 10:40 AM CT. A live audio webcast of these events will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be availabl

      5/7/25 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces Leadership Changes

      Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

      4/24/25 6:10:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend. First-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $698.0 million increased 0.4%; organic net sales growth was 2.1%.Reported-diluted EPS of $1.23, compared to $1.55 in the same period last year.Adjusted-diluted EPS of $1.45, compared to $1.56 in the same period last year.The Company is increasing its full yea

      4/24/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West to Host First-Quarter 2025 Conference Call

      EXTON, Pa., April 10, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 24, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone particip

      4/10/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West to Participate in Upcoming Investor Conferences

      EXTON, Pa., March 5, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 at 11:00 AM ET. It will also present at the KBCM Healthcare Forum on Wednesday, March 19, 2025 at 1:30 PM ET. A live audio webcast of these events will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be available for approximat

      3/5/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces Second-Quarter Dividend

      EXTON, Pa., Feb. 20, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2025 dividend of $0.21 per share. The dividend will be paid on May 7, 2025, to shareholders of record as of April 30, 2025. About West  West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps

      2/20/25 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces Fourth-Quarter and Full-Year 2024 Results

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Feb. 13, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the fourth-quarter and full-year 2024 and introduced 2025 financial guidance. Fourth-Quarter Summary (comparisons to prior-year period) & Full-Year 2025 Guidance Fourth-quarter 2024 net sales of $748.8 million increased 2.3%; organic net sales grew 3.3%.Fourth-quarter 2024 reported-diluted EPS of $1.78 declined 2.7%; fourth-quarter 2024 adjusted-diluted EPS of $1.82 declined 0.5%.For Full-year 2025,

      2/13/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West to Host Fourth-Quarter and Full-Year 2024 Conference Call

      EXTON, Pa., Jan. 30, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST),  global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 13, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website or by clicking here. To ask questions on the conference call, participant

      1/30/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces First-Quarter Dividend

      EXTON, Pa., Jan. 28, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a first-quarter 2025 dividend of $0.21 per share. The dividend will be paid on February 11, 2025, to shareholders of record as of February 7, 2025. About West   West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West

      1/28/25 12:00:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Introduces Daikyo PLASCAP® RUV Closures in New Nested Format at Pharmapack

      EXTON, Pa., Jan. 22, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the introduction of Daikyo PLASCAP® Ready-to-Use Validated (RUV) closures in a new nested format available in multiple configurations at this year's Pharmapack event in Paris, France.  This marks West's latest product offering supporting the needs of advanced therapies, one of the fastest growing areas, driven by continued innovation in cell and gene therapy treatments. The PLASCAP® closure is a met

      1/22/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    West Pharmaceutical Services Inc. SEC Filings

    See more
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      5/8/25 4:46:47 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by West Pharmaceutical Services Inc.

      10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      4/24/25 4:19:45 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      4/24/25 7:56:20 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      4/24/25 7:47:19 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      4/14/25 4:09:07 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by West Pharmaceutical Services Inc.

      DEFA14A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      3/21/25 4:07:14 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by West Pharmaceutical Services Inc.

      DEF 14A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      3/21/25 4:05:42 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form PRE 14A filed by West Pharmaceutical Services Inc.

      PRE 14A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      3/11/25 5:11:15 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      3/11/25 4:08:35 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by West Pharmaceutical Services Inc.

      10-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      2/18/25 4:44:56 PM ET
      $WST
      Medical/Dental Instruments
      Health Care

    West Pharmaceutical Services Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/13/24 5:17:38 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/14/23 12:37:59 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/10/22 8:47:14 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/4/22 11:53:53 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/16/21 12:23:44 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/10/21 12:00:05 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/2/21 3:14:13 PM ET
      $WST
      Medical/Dental Instruments
      Health Care

    West Pharmaceutical Services Inc. Financials

    Live finance-specific insights

    See more
    • West Announces Leadership Changes

      Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

      4/24/25 6:10:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend. First-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $698.0 million increased 0.4%; organic net sales growth was 2.1%.Reported-diluted EPS of $1.23, compared to $1.55 in the same period last year.Adjusted-diluted EPS of $1.45, compared to $1.56 in the same period last year.The Company is increasing its full yea

      4/24/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West to Host First-Quarter 2025 Conference Call

      EXTON, Pa., April 10, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 24, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone particip

      4/10/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces Second-Quarter Dividend

      EXTON, Pa., Feb. 20, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2025 dividend of $0.21 per share. The dividend will be paid on May 7, 2025, to shareholders of record as of April 30, 2025. About West  West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps

      2/20/25 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces Fourth-Quarter and Full-Year 2024 Results

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Feb. 13, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the fourth-quarter and full-year 2024 and introduced 2025 financial guidance. Fourth-Quarter Summary (comparisons to prior-year period) & Full-Year 2025 Guidance Fourth-quarter 2024 net sales of $748.8 million increased 2.3%; organic net sales grew 3.3%.Fourth-quarter 2024 reported-diluted EPS of $1.78 declined 2.7%; fourth-quarter 2024 adjusted-diluted EPS of $1.82 declined 0.5%.For Full-year 2025,

      2/13/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West to Host Fourth-Quarter and Full-Year 2024 Conference Call

      EXTON, Pa., Jan. 30, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST),  global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 13, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website or by clicking here. To ask questions on the conference call, participant

      1/30/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces First-Quarter Dividend

      EXTON, Pa., Jan. 28, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a first-quarter 2025 dividend of $0.21 per share. The dividend will be paid on February 11, 2025, to shareholders of record as of February 7, 2025. About West   West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West

      1/28/25 12:00:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares Fourth-Quarter 2024 Dividend

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Oct. 24, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Third-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%.Reported-diluted EPS of $1.85, compared to $2.14 in the same period last year.Adjusted-diluted EPS of $1.85, compared to $2.16 in the same period last year.As a result of favorable currency move

      10/24/24 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West to Host Third-Quarter 2024 Conference Call

      EXTON, Pa., Oct. 10, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 24, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website click here. To ask questions on the conference call, participants need to register in advance

      10/10/24 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces Second-Quarter 2024 Results

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance. Second-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $702.1 million declined 6.9%; organic net sales declined 5.9%.Reported-diluted EPS of $1.51, compared to $2.06 in the same period last year.Adjusted-diluted EPS of $1.52, compared to $2.11 in the same period last year. The Company is updating full-year 20

      7/25/24 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    West Pharmaceutical Services Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on West Pharm with a new price target

      Evercore ISI initiated coverage of West Pharm with a rating of Outperform and set a new price target of $275.00

      3/18/25 7:58:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharm upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded West Pharm from Hold to Buy and set a new price target of $250.00

      2/14/25 7:09:40 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Citigroup initiated coverage on West Pharm with a new price target

      Citigroup initiated coverage of West Pharm with a rating of Buy and set a new price target of $400.00

      1/8/25 8:35:06 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Wolfe Research initiated coverage on West Pharm

      Wolfe Research initiated coverage of West Pharm with a rating of Peer Perform

      12/13/24 8:34:44 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharm upgraded by UBS with a new price target

      UBS upgraded West Pharm from Neutral to Buy and set a new price target of $390.00 from $350.00 previously

      12/12/24 9:01:41 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharm upgraded by Jefferies with a new price target

      Jefferies upgraded West Pharm from Hold to Buy and set a new price target of $536.00 from $323.00 previously

      2/7/24 6:54:15 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharm upgraded by BofA Securities with a new price target

      BofA Securities upgraded West Pharm from Neutral to Buy and set a new price target of $405.00 from $390.00 previously

      6/16/23 7:27:08 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharm upgraded by Stephens with a new price target

      Stephens upgraded West Pharm from Equal-Weight to Overweight and set a new price target of $400.00 from $330.00 previously

      4/11/23 7:32:40 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Deutsche Bank initiated coverage on West Pharm with a new price target

      Deutsche Bank initiated coverage of West Pharm with a rating of Hold and set a new price target of $250.00

      12/14/22 8:21:22 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on West Pharm with a new price target

      UBS initiated coverage of West Pharm with a rating of Neutral and set a new price target of $250.00

      11/30/22 9:41:40 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    West Pharmaceutical Services Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Sotera Health Appoints Karen Flynn to Board of Directors

      CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

      11/13/23 7:00:14 AM ET
      $CTLT
      $QTRX
      $SHC
      $WST
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • West Announces Executive Leadership Appointments

      EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

      5/12/22 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care